Focused On-demand Library for Relaxin receptor 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9HBX9

UPID:

RXFP1_HUMAN

Alternative names:

Leucine-rich repeat-containing G-protein coupled receptor 7; Relaxin family peptide receptor 1

Alternative UPACC:

Q9HBX9; B4DHD1; B4DTV2; Q2M215; Q3KU24; Q3KU25; Q3KU26

Background:

Relaxin receptor 1, also known as leucine-rich repeat-containing G-protein coupled receptor 7, plays a pivotal role in mediating the effects of relaxins. These effects are achieved through the activation of G proteins, leading to an increase in adenylate cyclase activity and a subsequent rise in cAMP levels. Additionally, ligand binding may activate a tyrosine kinase pathway, further influencing cellular functions by inhibiting a phosphodiesterase that degrades cAMP.

Therapeutic significance:

Understanding the role of Relaxin receptor 1 could open doors to potential therapeutic strategies. Its involvement in key signaling pathways offers a unique opportunity to modulate various physiological processes, potentially addressing unmet medical needs.